The potential reassessment of cannabinoids, particularly at the federal level, is generating considerable buzz within the sector. A shift away from Schedule I status, often regarded as outdated and hindering innovation, could unlock significant opportunities for companies. Reduced regulatory impediments, alongside greater access to banking and capi